These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reply to Dr. Kotze's and Dr. Yamamoto's letter. Armuzzi A; Felice C J Crohns Colitis; 2013 Dec; 7(12):e699. PubMed ID: 23972685 [No Abstract] [Full Text] [Related]
3. Adalimumab or infliximab for the prevention or treatment of post-operative recurrence in Crohn's disease. Yamamoto T J Crohns Colitis; 2013 May; 7(4):e157. PubMed ID: 23021875 [No Abstract] [Full Text] [Related]
4. [Postoperative recurrence: adalimumab is an effective standard medication]. Hofmann-Aßmus M Z Gastroenterol; 2014 Mar; 52(3):260. PubMed ID: 24761446 [No Abstract] [Full Text] [Related]
5. Adalimumab for perianal fistulizing Crohn's disease: real-world data adds important information for clinical practice. Kotze PG; Spinelli A J Clin Gastroenterol; 2015 Feb; 49(2):174-5. PubMed ID: 25159683 [No Abstract] [Full Text] [Related]
6. Reply to Drs. Park & Shin's letter. Marques IN J Crohns Colitis; 2013 Aug; 7(7):601. PubMed ID: 23332559 [No Abstract] [Full Text] [Related]
7. Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs. Romano C; Sinagra E; Criscuoli V; Orlando A; Maisano S; Cottone M J Crohns Colitis; 2013 Oct; 7(9):e405-6. PubMed ID: 23764367 [No Abstract] [Full Text] [Related]
8. [Drug therapy of Crohn disease]. Niemelä S Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446 [No Abstract] [Full Text] [Related]
9. Histological inflammation in Crohn's disease in deep remission during treatment with anti-TNFα. Tursi A; Elisei W; Picchio M; Brandimarte G Dig Liver Dis; 2014 Jun; 46(6):575-6. PubMed ID: 24602485 [No Abstract] [Full Text] [Related]
10. Superficial abdominal thrombophlebitis (Mondor's disease) presenting as loss of response to adalimumab in a Crohn's disease patient. Ben-Horin S; Lubetsky A; Heyman Z; Kleinbaum Y J Crohns Colitis; 2014 Nov; 8(11):1557-8. PubMed ID: 24835166 [No Abstract] [Full Text] [Related]
11. Update on anti-tumor necrosis factor agents in Crohn disease. Singh S; Pardi DS Gastroenterol Clin North Am; 2014 Sep; 43(3):457-78. PubMed ID: 25110253 [TBL] [Abstract][Full Text] [Related]
12. Reply to Dr. Katsanos et al.'s letter. Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Gisbert JP J Crohns Colitis; 2013 Feb; 7(1):e23-4. PubMed ID: 22921467 [No Abstract] [Full Text] [Related]
13. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery. Doherty G; Moss AC Am J Gastroenterol; 2012 Mar; 107(3):487; author reply 487-8. PubMed ID: 22388032 [No Abstract] [Full Text] [Related]
14. Update on ustekinumab for the treatment of Crohn's disease. Leung Y; Panaccione R Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262 [TBL] [Abstract][Full Text] [Related]
15. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply. Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531 [No Abstract] [Full Text] [Related]
16. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. Papamichael K; Archavlis E; Lariou C; Mantzaris GJ J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843 [TBL] [Abstract][Full Text] [Related]